India Pharma Outlook Team | Monday, 09 November 2026
US pharma business opportunities continue to grow for companies that move beyond active pharmaceutical ingredient supply into finished prescription medicines.
Morepen Laboratories has launched Desloratadine tablets as its first US prescription generic drug product.
The company distributes the product through its wholly owned subsidiary, Morepen Bio Inc. , in 100-count and 500-count packs.
This launch marks a clear step forward in Morepen’s US pharma business and extends its reach beyond API manufacturing. The company now aims to build a broader portfolio of prescription generics in the competitive US market.
Morepen Laboratories already holds an established position as an API manufacturer. The firm has supplied Desloratadine API to the US market for several years. Launching the finished-dose Desloratadine product now shifts the company into a higher-value segment of the pharmaceutical business.
Supplying APIs means producing the key chemical ingredient that other firms formulate into final medicines. Marketing finished generic medicines allows a company to control formulation, packaging, regulatory compliance, and direct distribution. Morepen therefore captures more of the value chain.
Key benefits of this transition include:
Managing Director Sanjay Suri noted that long-standing API relationships in regulated markets provide a strong base for this next phase of growth. The company also expands its CDMO activities while selectively building finished-dosage capabilities and US distribution.
Also Read: Top 10 Performing Indian Pharma Stocks This Quarter (2026)
Morepen plans additional US product filings to expand its generic drug portfolio. The company has already submitted its first Abbreviated New Drug Application to the USFDA for Sitagliptin Phosphate Tablets in 25 mg, 50 mg, and 100 mg strengths.
This filing demonstrates Morepen’s intent to move beyond a single product. The company leverages its formulation development expertise, manufacturing capabilities, and regulatory experience gained from both API work and earlier OTC product introductions in the US. Building a broader portfolio reduces dependence on any one medicine and creates multiple growth avenues.
Successful regulatory approvals and effective commercial execution will help Morepen strengthen its position in the highly competitive US generics market. The firm may also evaluate opportunities in high-potency APIs and oncology in the future, subject to feasibility and market conditions. These steps reinforce the strategic shift in its US pharma business toward higher-value finished products.
Morepen’s Desloratadine launch signals a deliberate effort to capture greater value from its pharmaceutical capabilities. Its ability to expand filings, secure approvals, and commercialize additional products will determine the success of this transition in the US pharma business.
.jpg)
